Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis

Hernandez, Steve; López-Ribot, José L.; Najvar, Laura K.; McCarthy, Dora I.; Bocanegra, Rosie; Graybill, John R.

doi:10.1128/aac.48.4.1382-1383.2004

Cited by 162Antifungal resistance and susceptibilityFungal Plant Pathogen ControlFungal and yeast genetics research

Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis

Open access

Hernandez, Steve, López-Ribot, José L., Najvar, Laura K., McCarthy, Dora I., Bocanegra, Rosie, Graybill, John R.·2004·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.48.4.1382-1383.2004PMC PMC375251

Open this paper in CoChat — free account

Abstract

A patient with azole-refractory thrush-esophagitis responded initially to caspofungin, but the treatment eventually failed. In a murine model, caspofungin was effective against two early isolates for which the MICs of caspofungin were low, but it was less effective against a late isolate for which the MIC of caspofungin was greater. We concluded that there is a correlation between in vivo failure and rising in vitro caspofungin MICs.

Integrity signals

Registry

Crossref · 10.1128/aac.48.4.1382-1383.2004

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Reports of echinocandin resistance in patients with infections due to C. albicans, C. glabrata, C. tropicalis, and C. krusei are rising.
“However, reports of echinocandin resistance in patients with infections due to C. albicans, C. glabrata, C. tropicalis, and C. krusei are rising [111–116].”
From CandidaInfections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents (2013) · cites this paper as [111]
The frequency of diagnostic test ordering, especially blood cultures, and the type of blood culture systems may impact incidence rates in laboratory-based surveillance.
“Likewise, the frequency of diagnostic test ordering, especially of blood cultures, and the type of blood culture systems employed may also impact the incidence rates in laboratory-based surveillance (106, 259).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [106]
The isolation of C. glabrata may be increased in some blood culture systems (BacT/Alert versus BACTEC 9240) and in some blood culture media (BACTEC Mycosis IC/F versus BACTEC Plus Aerobic/F medium) over that observed in others.
“Although most surveillance studies have not specifically addressed the issue of differences among blood culture systems in the isolation of Candida species from blood, the isolation of C. glabrata may be increased in some blood culture systems (BacT/Alert versus BACTEC 9240) and in some blood culture media (BACTEC Mycosis IC/F versus BACTEC Plus Aerobic/F medium) over that observed in others (106,”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [106]

National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736 · see citing works
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380 · see citing works
A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia
Rex, J. H., Bennett, J. E., Sugar, A. M., Pappas, P. G., van der Horst, C. M., Edwards, J. E., Washburn, R. G., Scheld, W. M., Karchmer, A. W., Dine, A. P., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411173312001 · Cited by 1,039 · see citing works
Resistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 879 · see citing works
Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in Candida albicans Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · see citing works
Self-citation
Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors
Douglas, C. M., D'Ippolito, J. A., Shei, G.-J., Meinz, M., Onishi, J. C., Marrinan, J. A., Li, W., Abruzzo, G. K., Flattery, A. M., Bartizal, K. F., et al. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.11.2471 · Cited by 344 · see citing works
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
Wingard, J. R., Merz, W. G., Rinaldi, M. G., Miller, C. B., Karp, J. E., & Saral, R. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1847 · Cited by 339 · see citing works
Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases
Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., & Sable, C. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.451-457.2002 · Cited by 254 · see citing works
Fluconazole resistance in Candida glabrata
Hitchcock, C. A., Pye, G. W., Troke, P. F., Johnson, E. M., & Warnock, D. W. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.9.1962 · Cited by 244 · see citing works
Compounds active against cell walls of medically important fungi
Hector, R. F. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.1.1 · Cited by 242 · see citing works
Distinct Patterns of Gene Expression Associated with Development of Fluconazole Resistance in Serial Candida albicans Isolates from Human Immunodeficiency Virus-Infected Patients with Oropharyngeal Candidiasis
Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White, T. C., Sanglard, D., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2932 · Cited by 210 · see citing works
Self-citation
Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans and Cryptococcus neoformans
Ernst, E. J., Klepser, M. E., & Pfaller, M. A. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.1108-1111.2000 · Cited by 181 · see citing works
In Vitro Activities of Caspofungin Compared with Those of Fluconazole and Itraconazole against 3,959 Clinical Isolates of Candida spp., Including 157 Fluconazole-Resistant Isolates
Pfaller, M. A., Diekema, D. J., Messer, S. A., Hollis, R. J., & Jones, R. N. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1068-1071.2003 · Cited by 152 · see citing works
Correlation between in vitro resistance to fluconazole and clinical outcome of oropharyngeal candidiasis in HIV-infected patients
Quereda, C., Polanco, A. M., Giner, C., Sánchez-Sousa, A., Pereira, E., Navas, E., Fortün, J., Guerrero, A., & Baquero, F. (1996) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01586182 · Cited by 50 · see citing works
Antifungal Drugs and Resistance
Graybill, J. R. (1995) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-9203-4_19 · Cited by 4 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · see citing works
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619 · see citing works
Regulatory circuitry governing fungal development, drug resistance, and disease.
Shapiro, R. S., Robbins, N., & Cowen, L. E. (2011) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00045-10 · Cited by 576 · see citing works
Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins
Walker, L. A., Munro, C. A., de Bruijn, I., Lenardon, M. D., McKinnon, A., & Gow, N. A. R. (2008) · PLoS Pathogens · doi:10.1371/journal.ppat.1000040 · Cited by 445 · see citing works
Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates
Park, S., Kelly, R., Kahn, J. N., Robles, J., Hsu, M.-J., Register, E., Li, W., Vyas, V., Fan, H., Abruzzo, G., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3264-3273.2005 · Cited by 434 · see citing works
Mechanisms of Candida Biofilm Drug Resistance
Taff, H. T., Mitchell, K. F., Edward, J. A., & Andes, D. R. (2013) · Future Microbiology · doi:10.2217/fmb.13.101 · Cited by 422 · see citing works
CandidaInfections, Causes, Targets, and Resistance Mechanisms: Traditional and Alternative Antifungal Agents
Spampinato, C., & Leonardi, D. (2013) · BioMed Research International · doi:10.1155/2013/204237 · Cited by 411 · see citing works
In Vitro Susceptibility of Invasive Isolates of Candida spp. to Anidulafungin, Caspofungin, and Micafungin: Six Years of Global Surveillance
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Kroeger, J. S., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.01901-07 · Cited by 389 · see citing works
Evolution of antifungal-drug resistance: mechanisms and pathogen fitness
Anderson, J. B. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1179 · Cited by 375 · see citing works
Regulation of multidrug resistance in pathogenic fungi
Morschhäuser, J. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.08.002 · Cited by 300 · see citing works
Fungal echinocandin resistance
Walker, L. A., Gow, N. A. R., & Munro, C. A. (2010) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2009.09.003 · Cited by 267 · see citing works
Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints
Pfaller, M. A., Diekema, D. J., Ostrosky-Zeichner, L., Rex, J. H., Alexander, B. D., Andes, D., Brown, S. D., Chaturvedi, V., Ghannoum, M. A., Knapp, C. C., et al. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00566-08 · Cited by 250 · see citing works
In Vivo Comparison of the Pharmacodynamic Targets for Echinocandin Drugs against Candida Species
Andes, D., Diekema, D. J., Pfaller, M. A., Bohrmuller, J., Marchillo, K., & Lepak, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01584-09 · Cited by 226 · see citing works
The Echinocandins
Cappelletty, D., & Eiselstein‐McKitrick, K. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.3.369 · Cited by 205 · see citing works
Global Analysis of the Evolution and Mechanism of Echinocandin Resistance in Candida glabrata
Singh-Babak, S. D., Babak, T., Diezmann, S., Hill, J. A., Xie, J. L., Chen, Y.-L., Poutanen, S. M., Rennie, R. P., Heitman, J., & Cowen, L. E. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002718 · Cited by 204 · see citing works
“The most detailed sampling includes a clinical isolate pre-caspofungin treatment and two isolates taken serially post-caspofungin treatment, however, the mechanism by which resistance evolved was not investigated [50].”
Background
Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient
Krogh-Madsen, M., Arendrup, M. C., Heslet, L., & Knudsen, J. D. (2006) · Clinical Infectious Diseases · doi:10.1086/500939 · Cited by 201 · see citing works
Breakthrough invasive candidiasis in patients on micafungin.
Pfeiffer, C. D., Garcia-Effron, G., Zaas, A. K., Perfect, J. R., Perlin, D. S., & Alexander, B. D. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02390-09 · Cited by 196 · see citing works
In Vitro Susceptibilities of Candida spp. to Caspofungin: Four Years of Global Surveillance
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.44.3.760-763.2006 · Cited by 195 · see citing works
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis
Laverdière, M., LALONDE, R. G., Baril, J.-G., Sheppard, D. C., Park, S., & Perlin, D. S. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl022 · Cited by 192 · see citing works
Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility
Katiyar, S. K., Pfaller, M. A., & Edlind, T. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00349-06 · Cited by 189 · see citing works
Comparison of echinocandin antifungals
Eschenauer, G. A., DePestel, D. D., & Carver, P. L. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.1.71 · Cited by 184 · see citing works
TargetingCandida albicansfilamentation for antifungal drug development
Vila, T., Romo, J. A., Pierce, C. G., McHardy, S. F., Saville, S. P., & Lopez-Ribot, J. L. (2017) · Virulence · doi:10.1080/21505594.2016.1197444 · Cited by 174 · see citing works
Self-citation
Oropharyngeal candidiasis in the era of antiretroviral therapy
Thompson, G. R., Patel, P., Kirkpatrick, W. R., Westbrook, S. D., Berg, D., Erlandsen, J. E., Redding, S. W., & Patterson, T. F. (2010) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2009.11.026 · Cited by 164 · see citing works
Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection
Thompson, G. R., Wiederhold, N. P., Vallor, A. C., Villareal, N. C., Lewis, J. S., & Patterson, T. F. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00473-08 · Cited by 159 · see citing works
Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs
Pierce, C. G., & Lopez-Ribot, J. L. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.807245 · Cited by 158 · see citing works
Self-citation
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis - review of the literature
Kofla, G., & Ruhnke, M. (2011) · European Journal of Medical Research · doi:10.1186/2047-783x-16-4-159 · Cited by 153 · see citing works
Current status of antifungal susceptibility testing methods
Arikan, S. (2007) · Medical Mycology · doi:10.1080/13693780701436794 · Cited by 152 · see citing works
Acquired resistance to echinocandins in Candida albicans: case report and review
Baixench, M.-T., Aoun, N. B. T., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., & Dannaoui, É. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm095 · Cited by 149 · see citing works
Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy
Hakki, M., Staab, J. F., & Marr, K. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00148-06 · Cited by 148 · see citing works
Contemporary tools for the diagnosis and management of invasive mycoses
Alexander, B. D., & Pfaller, M. A. (2006) · Clinical Infectious Diseases · doi:10.1086/504491 · Cited by 147 · see citing works
In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model
Andes, D., Diekema, D. J., Pfaller, M. A., Prince, R. A., Marchillo, K., Ashbeck, J., & Hou, J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-07 · Cited by 140 · see citing works
Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome
Kartsonis, N. A., Killar, J., Mixson, L. A., Hoe, C., Sable, C. A., Bartizal, K. F., & Motyl, M. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3616-3623.2005 · Cited by 137 · see citing works
Overexpression ofCandida albicans CDR1,CDR2, orMDR1Does Not Produce Significant Changes in Echinocandin Susceptibility
Niimi, K., Maki, K., Ikeda, F., Holmes, A. R., Lamping, E., Niimi, M., Monk, B. C., & Cannon, R. D. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1148-1155.2006 · Cited by 134 · see citing works
Mutations in the fks1 Gene in Candida albicans , C. tropicalis , and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing
Desnos-Ollivier, M., Bretagne, S., Raoux, D., Hoinard, D., Dromer, F., & Dannaoui, E. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00088-08 · Cited by 132 · see citing works
Recent advances in antifungal chemotherapy
Petrikkos, G. L., & Skiada, A. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.03.009 · Cited by 127 · see citing works
Caspofungin
McCormack, P. L., & Perry, C. M. (2005) · Drugs · doi:10.2165/00003495-200565140-00009 · Cited by 122 · see citing works
A novel small molecule inhibitor of Candida albicans biofilm formation, filamentation and virulence with low potential for the development of resistance
Pierce, C. G., Chaturvedi, A. K., Lazzell, A. L., Powell, A. T., Saville, S. P., McHardy, S. F., & Lopez-Ribot, J. L. (2015) · npj Biofilms and Microbiomes · doi:10.1038/npjbiofilms.2015.12 · Cited by 124 · see citing works
Self-citation
Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing
Arendrup, M. C., García‐Effrón, G., Buzina, W., Mortensen, K. L., Reiter, N., Lundin, C., Jensen, H. E., Lass‐Flörl, C., Perlin, D. S., & Bruun, B. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01292-08 · Cited by 124 · see citing works
Antifungal drug resistance mechanisms
Pemán, J., Cantón, E., & Espinel‐Ingroff, A. (2009) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.09.18 · Cited by 121 · see citing works
Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome
Filioti, J., Spiroglou, K., & Roilides, E. (2007) · Intensive Care Medicine · doi:10.1007/s00134-007-0672-5 · Cited by 121 · see citing works
Use of Pharmacokinetic-Pharmacodynamic Analyses To Optimize Therapy with the Systemic Antifungal Micafungin for Invasive Candidiasis or Candidemia
Andes, D. R., Ambrose, P. G., Hammel, J., Wart, S. A. V., Iyer, V., Reynolds, D. K., Buell, D. N., Kovanda, L. L., & Bhavnani, S. M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01430-10 · Cited by 119 · see citing works
Echinocandins for Candidemia in Adults without Neutropenia
Bennett, J. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmct060052 · Cited by 109 · see citing works
Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species
García‐Effrón, G., Chua, D. J., Tomada, J. R. T., DiPersio, J. R., Perlin, D. S., Ghannoum, M. A., & Bonilla, H. F. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00998-09 · Cited by 104 · see citing works
Management of invasive fungal infections: a role for polyenes
Chandrasekar, P. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq479 · Cited by 100 · see citing works
Assessment of the Paradoxical Effect of Caspofungin in Therapy of Candidiasis
Clemons, K. V., Espiritu, M., Parmar, R., & Stevens, D. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1293-1297.2006 · Cited by 99 · see citing works
Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis
Barchiesi, F., Spreghini, E., Tomassetti, S., Della Vittoria, A., Arzeni, D., Manso, E., & Scalise, G. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00111-06 · Cited by 98 · see citing works
Resistance to Antifungal Drugs
Ben‐Ami, R., & Kontoyiannis, D. P. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.003 · Cited by 101 · see citing works
Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin
Miller, C., Lomaestro, B. W., Park, S., & Perlin, D. S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6.877 · Cited by 93 · see citing works
Gastrointestinal infections in immunocompromised hosts
Thom, K. A., & Forrest, G. N. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.mog.0000196149.29077.0d · Cited by 88 · see citing works
Supplement: Trends in invasive Candida infections and their treatment: focus on echinocandins
Lewis, R. E. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902990817 · Cited by 89 · see citing works
Epidemiology and antifungal resistance in invasive candidiasis
Rodloff, A., Koch, D., & Schaumann, R. (2011) · European journal of medical research · doi:10.1186/2047-783x-16-4-187 · Cited by 89 · see citing works
Global Surveillance of In Vitro Activity of Micafungin against Candida : a Comparison with Caspofungin by CLSI-Recommended Methods
Pfaller, M. A., Boyken, L. B., Hollis, R. J., Messer, S. A., Tendolkar, S., & Diekema, D. J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00872-06 · Cited by 88 · see citing works
Echinocandins in the management of invasive fungal infections, part 1
Morris, M. I., & Villmann, M. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050464.p1 · Cited by 86 · see citing works
Echinocandin antifungals: review and update
Morrison, V. A. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.2.325 · Cited by 85 · see citing works
Synthesis and in vitro activity of 2-thiazolylhydrazone derivatives compared with the activity of clotrimazole against clinical isolates of Candida spp.
Chimenti, F., Bizzarri, B., Maccioni, E., Secci, D., Bolasco, A., Fioravanti, R., Chimenti, P., Granese, A., Carradori, S., Rivanera, D., et al. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.05.078 · Cited by 82 · see citing works
Antifungal Susceptibility Testing: A Primer for Clinicians
Wiederhold, N. P. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab444 · Cited by 80 · see citing works
Echinocandins: A ray of hope in antifungal drug therapy
Grover, N. (2010) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.62396 · Cited by 75 · see citing works
In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Molina, D. K., Olivo, M., & Graybill, J. R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00105-07 · Cited by 74 · see citing works
Self-citation
Antimicrobial Resistance Prevention Initiative—An Update: Proceedings of an Expert Panel on Resistance
Moellering, R. C., Graybill, J. R., McGowan, J. E., & Corey, L. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.04.001 · Cited by 73 · see citing works
Self-citation
Isolation of culturable microorganisms from free-ranging bottlenose dolphins (Tursiops truncatus) from the southeastern United States
Morris, P. J., Johnson, W. R., Pisani, J., Bossart, G. D., Adams, J., Reif, J. S., & Fair, P. A. (2010) · Veterinary Microbiology · doi:10.1016/j.vetmic.2010.08.025 · Cited by 72 · see citing works
Canadian Clinical Practice Guidelines for Invasive Candidiasis in Adults
Bow, E. J., Evans, G. A., Fuller, J., Laverdière, M., Rotstein, C., Rennie, R. P., Shafran, S. D., Sheppard, D. C., Carle, S., Phillips, P., et al. (2010) · Canadian Journal of Infectious Diseases and Medical Microbiology · doi:10.1155/2010/357076 · Cited by 68 · see citing works
Synthesis and antimicrobial activity of some new hydrazone-bridged thiazole-pyrrole derivatives
Yurttaş, L., Özkay, Y., Kaplancıklı, Z. A., Tunalı, Y., & Karaca, H. (2012) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2012.688043 · Cited by 69 · see citing works
Clinical Evaluation of the Sensititre YeastOne Colorimetric Antifungal Panel for Antifungal Susceptibility Testing of the Echinocandins Anidulafungin, Caspofungin, and Micafungin
Pfaller, M. A., Chaturvedi, V. P., Diekema, D. J., Ghannoum, M. A., Holliday, N. M., Killian, S. B., Knapp, C. C., Messer, S. A., Miskov, A., & Ramani, R. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00493-08 · Cited by 68 · see citing works
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review
Sun, H., & Singh, N. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.09.020 · Cited by 66 · see citing works
Echinocandin pharmacodynamics: review and clinical implications
Pound, M. W., Townsend, M. L., & Drew, R. H. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq081 · Cited by 69 · see citing works
Clinical efficacy of new antifungal agents
Kauffman, C. A. (2006) · Current Opinion in Microbiology · doi:10.1016/j.mib.2006.08.001 · Cited by 64 · see citing works
The value of amphotericin B in the treatment of invasive fungal infections
Klepser, M. E. (2010) · Journal of Critical Care · doi:10.1016/j.jcrc.2010.08.005 · Cited by 63 · see citing works
Emergence of disseminated candidiasis caused byCandida kruseiduring treatment with caspofungin: Case report and review of literature
Pelletier, R., Alarie, I., Lagacé, R., & Walsh, T. J. (2005) · Medical Mycology · doi:10.1080/13693780500220415 · Cited by 59 · see citing works
The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety
Wiederhold, N. P., & Lewis, J. S. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1155 · Cited by 57 · see citing works
Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit
Ghannoum, M. A., Chen, A. W., Buhari, M. A., Chandra, J., Mukherjee, P. K., Baxa, D. M., Golembieski, A., & Vázquez, J. A. (2009) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02660.x · Cited by 55 · see citing works
Recent insights into the mechanisms of antifungal resistance
Barker, K. S., & Rogers, P. D. (2006) · Current Infectious Disease Reports · doi:10.1007/s11908-006-0019-3 · Cited by 54 · see citing works
Initial results from a longitudinal international surveillance programme for anidulafungin (2003)
Messer, S. A., Kirby, J. T., Sader, H. S., Fritsche, T. R., & Jones, R. N. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh504 · Cited by 52 · see citing works
Pyrosequencing To Detect Mutations in FKS1 That Confer Reduced Echinocandin Susceptibility in Candida albicans
Wiederhold, N. P., Grabinski, J. L., García‐Effrón, G., Perlin, D. S., & Lee, S. A. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00959-08 · Cited by 51 · see citing works
Emerging echinocandins for treatment of invasive fungal infections
Turner, M., Drew, R. H., & Perfect, J. R. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.2.231 · Cited by 49 · see citing works
Clinically significant micafungin resistance in Candida albicans involves modification of a glucan synthase catalytic subunit GSC1 (FKS1) allele followed by loss of heterozygosity
Niimi, K., Monk, B. C., Hirai, A., Hatakenaka, K., Umeyama, T., Lamping, E., Maki, K., Tanabe, K., Kamimura, T., Ikeda, F., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq073 · Cited by 47 · see citing works
Inhibition of Candida parapsilosis Mitochondrial Respiratory Pathways Enhances Susceptibility to Caspofungin
Chamilos, G., Lewis, R. E., & Kontoyiannis, D. P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.744-747.2006 · Cited by 47 · see citing works
Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.
Jensen, R. H., Johansen, H. K., & Arendrup, M. C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01193-12 · Cited by 47 · see citing works
Distribution of clinical isolates of Candida spp. and antifungal susceptibility of high biofilm-forming Candida isolates
Şahal, G., & Bilkay, I. S. (2018) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0136-2018 · Cited by 46 · see citing works
A Phase 2, Open-Label Study of the Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis
Vázquez, J. A., Schranz, J., Clark, K., Goldstein, B. P., Reboli, A. C., & Fichtenbaum, C. J. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31817af47a · Cited by 45 · see citing works
Echinocandins: role in antifungal therapy, 2005
Zaas, A. K., & Alexander, B. D. (2005) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.6.10.1657 · Cited by 45 · see citing works
Susceptibility patterns of Candida species recovered from Canadian intensive care units
Laverdiere, M., Labbé, A.-C., Restieri, C., Rotstein, C., Heyland, D., Madger, S., & Stewart, T. (2007) · Journal of Critical Care · doi:10.1016/j.jcrc.2006.10.038 · Cited by 42 · see citing works
Echinocandin Resistance in Candida Species: a Review of Recent Developments
Wiederhold, N. P. (2016) · Current Infectious Disease Reports · doi:10.1007/s11908-016-0549-2 · Cited by 41 · see citing works
Effect of the crude extract of Eugenia uniflora in morphogenesis and secretion of hydrolytic enzymes in Candida albicans from the oral cavity of kidney transplant recipients
Rocha, W. P. D. S., Lemos, V. L. D. B., Ferreira, M. R. A., Soares, L. A. L., Svidzisnki, T. I. E., Milan, E. P., & Chaves, G. M. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0522-x · Cited by 40 · see citing works
In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan
Yamazaki, T., Inagaki, Y., Fujii, T., Ohwada, J., Tsukazaki, M., UMEDA, I., Kobayashi, K., Shimma, N., Page, M. G. P., & Arisawa, M. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2010.06.003 · Cited by 40 · see citing works
In Vitro Pharmacodynamics of Anidulafungin and Caspofungin against Candida glabrata Isolates, Including Strains with Decreased Caspofungin Susceptibility
Cota, J. M., Carden, M., Graybill, J. R., Najvar, L. K., Burgess, D. S., & Wiederhold, N. P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00538-06 · Cited by 40 · see citing works
Self-citation
Antimicrobial resistance prevention initiative—an update: Proceedings of an expert panel on resistance
Moellering, R. C., Graybill, J. R., McGowan, J. E., & Corey, L. (2007) · American Journal of Infection Control · doi:10.1016/j.ajic.2007.08.001 · Cited by 38 · see citing works
Self-citation
Anidulafungin: review of a new echinocandin antifungal agent
Raasch, R. H. (2004) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2.4.499 · Cited by 38 · see citing works
FKS2 Mutations Associated with Decreased Echinocandin Susceptibility of Candida glabrata following Anidulafungin Therapy
Costa‐de‐Oliveira, S., Miranda, I. M., Silva, R. M., Silva, A. P., Rocha, R., Amorim, A., Rodrigues, A. G., & Pina‐Vaz, C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00589-10 · Cited by 37 · see citing works
Biochemical characterization of an anti-Candida factor produced by Enterococcus faecalis
Shekh, M. R., & Roy, U. (2012) · BMC Microbiology · doi:10.1186/1471-2180-12-132 · Cited by 37 · see citing works
Anidulafungin: an echinocandin antifungal
Pfaller, M. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1183 · Cited by 37 · see citing works
Detection of Caspofungin Resistance in Candida spp. by Etest
Desnos‐Ollivier, M., Dromer, F., & Dannaoui, É. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00053-08 · Cited by 35 · see citing works
Interactions of Yeasts, Moulds, and Antifungal Agents
Hall, G. S. (2011) · Humana Press eBooks · doi:10.1007/978-1-59745-134-5 · Cited by 33 · see citing works
Invasive Candida infections in the neonate
Smith, P. B., Steinbach, W. J., & Benjamin, D. K. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.007 · Cited by 33 · see citing works
Susceptibility testing of Candida albicans isolated from oropharyngeal mucosa of HIV+ patients to fluconazole, amphotericin B and Caspofungin: killing kinetics of caspofungin and amphotericin B against fluconazole resistant and susceptible isolates
Lemos, J. D. A., Costa, C. R., de Araújo, C. R., Souza, L. K. H. E., & Silva, M. D. R. R. (2009) · Brazilian Journal of Microbiology · doi:10.1590/s1517-83822009000100028 · Cited by 33 · see citing works
Invasive mold infections: recent advances in management approaches
Chandrasekar, P. H. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902777434 · Cited by 31 · see citing works
In Vitro Interaction of Posaconazole and Caspofungin against Clinical Isolates of Candida glabrata
Oliveira, E. R., Fothergill, A. W., Kirkpatrick, W. R., Coco, B. J., Patterson, T. F., & Redding, S. W. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.8.3544-3545.2005 · Cited by 31 · see citing works
In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis
Fan, S., & Liu, X. P. (2010) · Mycoses · doi:10.1111/j.1439-0507.2010.01887.x · Cited by 29 · see citing works
Micafungin
Carter, N. J., & Keating, G. M. (2009) · Pediatric Drugs · doi:10.2165/00148581-200911040-00006 · Cited by 28 · see citing works
The pharmacology and clinical use of caspofungin
Hope, W. W., Shoham, S., & Walsh, T. J. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.263 · Cited by 28 · see citing works
Future therapies targeted towards eliminatingCandidabiofilms and associated infections
Bandara, N., Matsubara, V. H., & Samaranayake, L. P. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1268530 · Cited by 29 · see citing works

Acquired resistance to echinocandins in Candida albicans: case report and review
Baixench, M.-T., Aoun, N. B. T., Desnos‐Ollivier, M., Garcia‐Hermoso, D., Bretagne, S., Ramires, S., Piketty, C., & Dannaoui, É. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm095 · Cited by 149 · see citing works
Progressive Esophagitis Caused by Candida albicans with Reduced Susceptibility to Caspofungin
Miller, C., Lomaestro, B. W., Park, S., & Perlin, D. S. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.6.877 · Cited by 93 · see citing works
Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy
Hakki, M., Staab, J. F., & Marr, K. A. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00148-06 · Cited by 148 · see citing works
Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome
Kartsonis, N. A., Killar, J., Mixson, L. A., Hoe, C., Sable, C. A., Bartizal, K. F., & Motyl, M. R. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3616-3623.2005 · Cited by 137 · see citing works
Caspofungin Dose Escalation for Invasive Candidiasis Due to Resistant Candida albicans
Wiederhold, N. P., Najvar, L. K., Bocanegra, R. A., Kirkpatrick, W. R., & Patterson, T. F. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01750-10 · Cited by 61 · see citing works
Self-citation

Authors: Hernandez, S., López-Ribot, J. L., Najvar, L. K., McCarthy, D. I., Bocanegra, R., & Graybill, J. R.
Affiliations: Department of Medicine, Division Infectious Diseases (7881)
The University of Texas at San Antonio Health Science Center (US)
Corresponding author: Hernandez, Steve
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2004-04
Volume: 48
Issue: 4
Pages: 1382-1383
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.48.4.1382-1383.2004
PMC: PMC375251
OpenAlex: W2133731564
Cited by: 162
References: 15
Citations by year: 2024: 1 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 3 · 2015: 3 · 2014: 2 · 2013: 8 · 2012: 9
FWCI: 13.12
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
Keywords: caspofungin resistance, Candida albicans, serial isolates, minimum inhibitory concentration, antifungal susceptibility testing, clinical outcomes, mouse model, treatment failure
MeSH terms: Caspofungin, Acquired Immunodeficiency Syndrome, Adult, Animals, Antifungal Agents, Candida albicans, Candidiasis, Esophagitis, Humans, Male, Mice, Inbred ICR, Microbial Sensitivity Tests, Peptides, Peptides, Cyclic, Treatment Failure, Drug Resistance, Fungal, Mice, Echinocandins, Lipopeptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks